J&J loses patent suit over dementia med

Seven generics makers are high-fiving today after a federal judge declared Johnson & Johnson's patent on Alzheimer's med Razadyne invalid. The ruling is the latest development in a long-standing dispute over the patent that started when J&J sued the copycats to keep their versions off the market. Now, J&J says it will appeal the judge's decision, but Barr, for one, says it's going to launch its generics straight away. So does Mylan.

The other generics makers involved are Teva--which is buying Barr--plus Dr. Reddy's Laboratories, Par Pharmaceuticals, and units of Actavis and Merck KGaA. Razadyne accounted for $214 million of J&J's 2007 sales.

- read J&J's Ortho-McNeil release
- check out the story in the Star-Ledger
- see the Interactive Investor news
- get the Wall Street Journal article

 

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.